-+ 0.00%
-+ 0.00%
-+ 0.00%

ACADIA Pharmaceuticals publishes 2025 annual report

PUBT·04/28/2026 19:12:49
Listen to the news
ACADIA Pharmaceuticals publishes 2025 annual report
  • Acadia annual report for fiscal 2025 flagged first year above USD 1 billion in annual revenue, supported by continued momentum in NUPLAZID, DAYBUE.
  • DAYBUE franchise highlighted global expansion, with approvals in additional markets including Israel; company also secured FDA clearance for DAYBUE STIX formulation.
  • Pipeline update centered on remlifanserin for Alzheimer’s disease psychosis, with Phase 2 enrollment targeted for completion in first half of 2026; top-line data expected August to October 2026.
  • Development program in Lewy body dementia psychosis advanced with Phase 2 study initiation in September 2025.
  • Acadia ended ACP-101 development in Prader-Willi syndrome following Phase 3 results that missed primary endpoint.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.